AVITHRAPID

The European Consortium ""Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases"" (AVITHRAPID). The aim of the project is to establish a pipeline of small molecule-based antiviral agents that can be widely used and rapidly developed into therapies against emerging infectious diseases. As part of the project, the consortium intends to test a small molecule against Zika virus in a clinical trial. The European consortium "Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases" AVITHRAPID is part of the EU Horizon research programme call "Pandemic preparedness and response: Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential". The AVITHRAPID research consortium comprises 18 research institutions and companies from 8 countries, coordinated by the German Fraunhofer-Gesellschaft. AVITHRAPID started in January 2024 with a duration of 54 months .The Swiss Partners in the AVITHRAPID consortium are funded by the Swiss State Secretariat for Education, Research and Innovation SERI.